Valneva SE American Depositary Shares (VALN)
Company News
Law firm investigating potential securities law violations by Valneva after CDC and FDA raised safety concerns about its chikungunya virus vaccine IXCHIQ, leading to significant stock price drops.
Brazil has approved Valneva's single-dose chikungunya vaccine, Ixchiq, for individuals 18 years and older. The approval enables large-scale clinical trials and expands access to the vaccine in low- and middle-income countries.
Valneva's single-dose Chikungunya vaccine, IXCHIQ, has received marketing authorization from the European Commission. This approval follows the FDA's nod in November 2023 and positions Valneva to protect European populations against Chikungunya outbreaks. The global Chikungunya vaccine market is expected to grow significantly, driven by rising medical needs and increased vaccine research and development.
The company is doubling down on its vaccine success.
Get ready for a big change in how the U.S. will pay for COVID-19 vaccines and treatments.